Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response, safety and efficacy of JN.1-strain mRNA and replicon COVID-19 vaccines in adults
jRCT1031240710Recruiting
- Sponsor
- NA
- Start
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of COVID-19 mRNA vaccine (JN.1 strain-compatible) and ARCT-2301 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by NA. Primary endpoints: Immune response to JN.1 strain-compatible COVID-19 vaccines, Vaccine efficacy assessment and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
COVID-19 mRNA vaccine (JN.1 strain-compatible)ARCT-2301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1031240710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240710.